First Generic Version of Gilead’s HIV Drug Approved By FDA

The FDA has announced that it has approved Teva’s copycat version of Gilead’s Truvada. Truvada is used to treat HIV in conjunction with other antiretroviral drugs, and in 2012 it also gained approval to prevent sexually transmitted HIV-1 infections in uninfected adults. According to Gilead’s records, about 125,000 people in the US are taking Truvada as of the first quarter of 2017. The drug made $3.5 billion in global sales for Gilead in 2016. Gilead has sued other generic drugmakers attempting to produce a Truvada copycat in the past, including Lupin, Cipla, and Amneal Pharmaceuticals.

Read the source article at Yahoo Finance